POM-V
Prescription Required
Companion Animal
Sporimune 50 mg/ml Oral Solution for Cats and Dogs
Active ingredient: Ciclosporin A
Form
Liquid
Species
Cats
Dogs
Manufacturer
Le Vet Beheer B.V.
VMD MA No.
41821/4017
What it's used for
Symptomatic treatment of chronic allergic dermatitis in cats.
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Ciclosporin A
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Sporimune 50 mg/ml Oral Solution for Cats and Dogs — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
Symptomatic treatment of chronic allergic dermatitis in cats.
Before starting treatment, an evaluation of all alternative treatment options should be
made.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
At first use: replace the original screw cap of the bottle with the separately delivered
screw cap. Fill the correct dosing syringe by pulling the plunger until it reaches the
graduation corresponding to the correct body weight of the animal. After
administration of the veterinary medicinal product close bottle tightly with cap, wash
the measuring syringe with water and let it dry.
Dosage and method of administration
Dogs
The mean recommended dose of ciclosporin is 5 mg per kg body weight (0.25 ml oral
solution per 2.5 kg bodyweight). The veterinary medicinal product should be given at
least 2 hours before or after feeding.
The veterinary medicinal product should be administered directly into the dog’s
mouth on the back of the tongue using the graduated dosing syringe supplied (1 ml
oral solution contains 50 mg ciclosporin) and delivering the entire dose.
Cats
The recommended dose of ciclosporin is 7 mg/kg body weight (0.14 ml of oral
solution per kg) and should initially be administered daily. The frequency of
administration should subsequently be reduced depending on the response. The
veterinary medicinal product can be given either mixed with food or directly into the
mouth. If given with food, the solution should be mixed with half the normal amount of
food consumed using the graduated dosing syringe supplied. (1 ml oral solution
contains 50 mg ciclosporin), preferably after a sufficient period of fasting to ensure
complete consumption by the cat. When the medicated feed is fully consumed the
rest of the food may be given.
Should the cat not accept the veterinary medicinal product mixed with food, it should
be given by inserting the syringe directly into the cat’s mouth and delivering the entire
dose. If the cat only partially eats the veterinary medicinal product mixed with food,
administration of the veterinary medicinal product directly into the mouth using the
graduated dosing syringe must only be continued the next day.
Duration and frequency of administration
The veterinary medicinal product will initially be given daily until a satisfactory clinical
improvement is seen (assessed by intensity of pruritus and lesion severity -
excoriations, miliary dermatitis, eosinophilic plaques and/or self-induced alopecia).
This will generally be the case within 4-8 weeks. If no response is obtained within the
first 8 weeks, the treatment should be stopped.
Once the clinical signs of atopic/allergic dermatitis are satisfactorily controlled, the
preparation can then be given every other day as a maintenance dose. The
veterinarian should perform a clinical assessment at regular intervals and adjust the
frequency of administration to the clinical response obtained.
In some cases where the clinical signs are controlled with every-other-day dosing,
the veterinarian can decide to give the veterinary medicinal product every 3 to 4
AN: 01235/2024 & 01239/2024
days. The lowest effective frequency of dosing should be used to maintain the
remission of clinical signs.
Adjunct treatment (e.g. medicated shampoos, fatty acids) may be considered before
reducing the dosing interval. Patients should be regularly re-evaluated and alternative
treatment options reviewed.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
made.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
At first use: replace the original screw cap of the bottle with the separately delivered
screw cap. Fill the correct dosing syringe by pulling the plunger until it reaches the
graduation corresponding to the correct body weight of the animal. After
administration of the veterinary medicinal product close bottle tightly with cap, wash
the measuring syringe with water and let it dry.
Dosage and method of administration
Dogs
The mean recommended dose of ciclosporin is 5 mg per kg body weight (0.25 ml oral
solution per 2.5 kg bodyweight). The veterinary medicinal product should be given at
least 2 hours before or after feeding.
The veterinary medicinal product should be administered directly into the dog’s
mouth on the back of the tongue using the graduated dosing syringe supplied (1 ml
oral solution contains 50 mg ciclosporin) and delivering the entire dose.
Cats
The recommended dose of ciclosporin is 7 mg/kg body weight (0.14 ml of oral
solution per kg) and should initially be administered daily. The frequency of
administration should subsequently be reduced depending on the response. The
veterinary medicinal product can be given either mixed with food or directly into the
mouth. If given with food, the solution should be mixed with half the normal amount of
food consumed using the graduated dosing syringe supplied. (1 ml oral solution
contains 50 mg ciclosporin), preferably after a sufficient period of fasting to ensure
complete consumption by the cat. When the medicated feed is fully consumed the
rest of the food may be given.
Should the cat not accept the veterinary medicinal product mixed with food, it should
be given by inserting the syringe directly into the cat’s mouth and delivering the entire
dose. If the cat only partially eats the veterinary medicinal product mixed with food,
administration of the veterinary medicinal product directly into the mouth using the
graduated dosing syringe must only be continued the next day.
Duration and frequency of administration
The veterinary medicinal product will initially be given daily until a satisfactory clinical
improvement is seen (assessed by intensity of pruritus and lesion severity -
excoriations, miliary dermatitis, eosinophilic plaques and/or self-induced alopecia).
This will generally be the case within 4-8 weeks. If no response is obtained within the
first 8 weeks, the treatment should be stopped.
Once the clinical signs of atopic/allergic dermatitis are satisfactorily controlled, the
preparation can then be given every other day as a maintenance dose. The
veterinarian should perform a clinical assessment at regular intervals and adjust the
frequency of administration to the clinical response obtained.
In some cases where the clinical signs are controlled with every-other-day dosing,
the veterinarian can decide to give the veterinary medicinal product every 3 to 4
AN: 01235/2024 & 01239/2024
days. The lowest effective frequency of dosing should be used to maintain the
remission of clinical signs.
Adjunct treatment (e.g. medicated shampoos, fatty acids) may be considered before
reducing the dosing interval. Patients should be regularly re-evaluated and alternative
treatment options reviewed.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
Do not use in dogs less than six months of age or less than 2 kg in weight.
Do not use in cases with a history of malignant disorders or progressive malignant
disorders.
Do not use in cats infected with FeLV or FIV.
AN: 01235/2024 & 01239/2024
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not vaccinate with a live vaccine during treatment or within a two-week interval
before or after treatment (see also sections 3.5 “Special precautions for use” and 3.8
“Interaction with other medicinal products and other forms of interaction”).
Do not use in cases with a history of malignant disorders or progressive malignant
disorders.
Do not use in cats infected with FeLV or FIV.
AN: 01235/2024 & 01239/2024
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not vaccinate with a live vaccine during treatment or within a two-week interval
before or after treatment (see also sections 3.5 “Special precautions for use” and 3.8
“Interaction with other medicinal products and other forms of interaction”).
Dogs:
AN: 01235/2024 & 01239/2024
Very common
(>1 animal / 10 animals
treated):
Digestive tract disorders (e.g. Vomiting, Loose
stool, Mucous stool, Diarrhoea)
a
Uncommon
(1 to 10 animals / 1,000 animals
treated):
Lethargy
c
, Anorexia
c
Hyperactivity
c
Gingival hyperplasia
b,c
Skin lesions (e.g. Verruciform lesion, Hair change)
c
Pinnal reddening
c
, Pinnal oedema
c
Muscle weakness
c
, Cramp
c
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Diabetes Mellitus
d
a
Mild and transient and generally do not require cessation of treatment.
b
Mild to moderate.
c
These effects generally resolve spontaneously after treatment is stopped.
d
Mainly in West Highland White Terriers.
As for the subject of malignancy, please see sections 3.3 “Contraindications” and 3.5
“Special
precautions for use”.
Cats:
Very common
(>1 animal / 10 animals
treated):
Digestive tract disorders (e.g. Vomiting,
Diarrhoea)
a
Common
(1 to 10 animals / 100 animals
treated):
Lethargy
b
, Anorexia
b
, Weight loss
b
Hypersalivation
b
Lymphopenia
b
a
Generally mild and transient and do not require cessation of treatment.
b
These effects generally resolve spontaneously after treatment is stopped or
following a decrease in
the dosing frequency.
Side effects may be severe in individual animals.
As for the subject of malignancy, please see sections 3.3 “Contraindications” and 3.5
“Special
precautions for use”.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
AN: 01235/2024 & 01239/2024
competent authority via the national reporting system. See the package leaflet for
respective contact details.
AN: 01235/2024 & 01239/2024
Very common
(>1 animal / 10 animals
treated):
Digestive tract disorders (e.g. Vomiting, Loose
stool, Mucous stool, Diarrhoea)
a
Uncommon
(1 to 10 animals / 1,000 animals
treated):
Lethargy
c
, Anorexia
c
Hyperactivity
c
Gingival hyperplasia
b,c
Skin lesions (e.g. Verruciform lesion, Hair change)
c
Pinnal reddening
c
, Pinnal oedema
c
Muscle weakness
c
, Cramp
c
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Diabetes Mellitus
d
a
Mild and transient and generally do not require cessation of treatment.
b
Mild to moderate.
c
These effects generally resolve spontaneously after treatment is stopped.
d
Mainly in West Highland White Terriers.
As for the subject of malignancy, please see sections 3.3 “Contraindications” and 3.5
“Special
precautions for use”.
Cats:
Very common
(>1 animal / 10 animals
treated):
Digestive tract disorders (e.g. Vomiting,
Diarrhoea)
a
Common
(1 to 10 animals / 100 animals
treated):
Lethargy
b
, Anorexia
b
, Weight loss
b
Hypersalivation
b
Lymphopenia
b
a
Generally mild and transient and do not require cessation of treatment.
b
These effects generally resolve spontaneously after treatment is stopped or
following a decrease in
the dosing frequency.
Side effects may be severe in individual animals.
As for the subject of malignancy, please see sections 3.3 “Contraindications” and 3.5
“Special
precautions for use”.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
AN: 01235/2024 & 01239/2024
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Consideration should be given to the use of other measures and/or treatments to
control moderate to severe pruritus when initiating therapy with ciclosporin.
Special precautions for safe use in the target species:
Clinical signs of atopic dermatitis in dogs and allergic dermatitis in cats such as
pruritus and skin inflammation are not specific for this disease. Therefore, other
causes of dermatitis such as ectoparasitic infestations, other allergies which cause
dermatological signs (e.g. flea allergic dermatitis or food allergy) or bacterial and
fungal infections should be evaluated and eliminated where possible. It is good
practice to treat flea infestations before and during treatment of atopic and allergic
dermatitis.
A complete clinical examination should be performed before treatment.
Any infections should be properly treated before initiation of treatment. Infections
occurring during treatment are not necessarily a reason for drug withdrawal, unless
the infection is severe.
Particular attention must be paid to vaccination. Treatment with the veterinary
medicinal product may interfere with vaccination efficacy. In the case of inactivated
vaccines, it is not recommended to vaccinate during treatment or within a two-week
interval before or after administration of the veterinary medicinal product. For live
vaccines see also section 3.3 “Contraindications”.
It is not recommended to use other immunosuppressive agents concomitantly.
In laboratory animals, ciclosporin is liable to affect the circulating levels of insulin and
to cause an increase in glycaemia. In the presence of suggestive signs of diabetes
mellitus, the effect of treatment on glycaemia must be monitored. If signs of diabetes
mellitus are observed following the use of the veterinary medicinal product, e.g.
polyuria or polydipsia, the dose should be tapered or discontinued and veterinary
care sought. The use of ciclosporin is not recommended in diabetic animals.
While ciclosporin does not induce tumours, it does inhibit T-lymphocytes and
therefore treatment with ciclosporin may lead to an increased incidence of clinically
apparent malignancy due to the decrease in antitumour immune response. The
potentially increased risk of tumour progression must be weighed against the clinical
benefit. If lymphadenopathy is observed in animals being treated with ciclosporin,
further clinical investigations are recommended and treatment discontinued if
necessary.
AN: 01235/2024 & 01239/2024
Dogs
Closely monitor creatinine levels in dogs with severe renal insufficiency.
Cats
Allergic dermatitis in cats can have various manifestations, including eosinophilic
plaques, head and neck excoriation, symmetrical alopecia and/or miliary dermatitis.
The immune status of the cats to FeLV and FIV infections should be assessed before
treatment.
Cats that are seronegative for T. gondii may be at risk of developing clinical
toxoplasmosis if they become infected while under treatment. In rare cases this can
be fatal. Potential exposure of seronegative cats or cats suspected to be
seronegative to Toxoplasma
raw meat or scavenging). Ciclosporin was shown to not increase T. gondii
shedding in a controlled laboratory study. In cases of clinical toxoplasmosis or other
serious systemic illness, stop treatment with ciclosporin and initiate appropriate
therapy.
Clinical studies in cats have shown that decreased appetite and weight loss may
occur during ciclosporin treatment. Monitoring of body weight is recommended.
Significant reduction in body weight may result in hepatic lipidosis. If persistent,
progressive weight loss occurs during treatment it is recommended to discontinue
treatment until the cause has been identified.
The efficacy and safety of ciclosporin has neither been assessed in cats less than 6
months of age nor weighing less than 2.3 kg.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Accidental ingestion of this veterinary medicinal product may lead to nausea and/or
vomiting. To avoid accidental ingestion, the veterinary medicinal product must be
used and kept out of reach of children. Do not leave unattended filled syringe in the
presence of children. Any uneaten medicated cat food must be disposed of
immediately and the bowl washed thoroughly.
In case of accidental ingestion, particularly by a child, seek medical advice
immediately and show the package leaflet or the label to the physician.
Ciclosporin can trigger hypersensitivity (allergic) reactions.
People with known hypersensitivity to ciclosporin should avoid contact with the
veterinary medicinal product.
Irritation to eyes is unlikely. As precautionary measure avoid contact with eyes. In
case of contact, rinse thoroughly with clean water. Wash hands and any exposed
skin after use.
Special precautions for the protection of the environment:
Not applicable.
control moderate to severe pruritus when initiating therapy with ciclosporin.
Special precautions for safe use in the target species:
Clinical signs of atopic dermatitis in dogs and allergic dermatitis in cats such as
pruritus and skin inflammation are not specific for this disease. Therefore, other
causes of dermatitis such as ectoparasitic infestations, other allergies which cause
dermatological signs (e.g. flea allergic dermatitis or food allergy) or bacterial and
fungal infections should be evaluated and eliminated where possible. It is good
practice to treat flea infestations before and during treatment of atopic and allergic
dermatitis.
A complete clinical examination should be performed before treatment.
Any infections should be properly treated before initiation of treatment. Infections
occurring during treatment are not necessarily a reason for drug withdrawal, unless
the infection is severe.
Particular attention must be paid to vaccination. Treatment with the veterinary
medicinal product may interfere with vaccination efficacy. In the case of inactivated
vaccines, it is not recommended to vaccinate during treatment or within a two-week
interval before or after administration of the veterinary medicinal product. For live
vaccines see also section 3.3 “Contraindications”.
It is not recommended to use other immunosuppressive agents concomitantly.
In laboratory animals, ciclosporin is liable to affect the circulating levels of insulin and
to cause an increase in glycaemia. In the presence of suggestive signs of diabetes
mellitus, the effect of treatment on glycaemia must be monitored. If signs of diabetes
mellitus are observed following the use of the veterinary medicinal product, e.g.
polyuria or polydipsia, the dose should be tapered or discontinued and veterinary
care sought. The use of ciclosporin is not recommended in diabetic animals.
While ciclosporin does not induce tumours, it does inhibit T-lymphocytes and
therefore treatment with ciclosporin may lead to an increased incidence of clinically
apparent malignancy due to the decrease in antitumour immune response. The
potentially increased risk of tumour progression must be weighed against the clinical
benefit. If lymphadenopathy is observed in animals being treated with ciclosporin,
further clinical investigations are recommended and treatment discontinued if
necessary.
AN: 01235/2024 & 01239/2024
Dogs
Closely monitor creatinine levels in dogs with severe renal insufficiency.
Cats
Allergic dermatitis in cats can have various manifestations, including eosinophilic
plaques, head and neck excoriation, symmetrical alopecia and/or miliary dermatitis.
The immune status of the cats to FeLV and FIV infections should be assessed before
treatment.
Cats that are seronegative for T. gondii may be at risk of developing clinical
toxoplasmosis if they become infected while under treatment. In rare cases this can
be fatal. Potential exposure of seronegative cats or cats suspected to be
seronegative to Toxoplasma
raw meat or scavenging). Ciclosporin was shown to not increase T. gondii
shedding in a controlled laboratory study. In cases of clinical toxoplasmosis or other
serious systemic illness, stop treatment with ciclosporin and initiate appropriate
therapy.
Clinical studies in cats have shown that decreased appetite and weight loss may
occur during ciclosporin treatment. Monitoring of body weight is recommended.
Significant reduction in body weight may result in hepatic lipidosis. If persistent,
progressive weight loss occurs during treatment it is recommended to discontinue
treatment until the cause has been identified.
The efficacy and safety of ciclosporin has neither been assessed in cats less than 6
months of age nor weighing less than 2.3 kg.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Accidental ingestion of this veterinary medicinal product may lead to nausea and/or
vomiting. To avoid accidental ingestion, the veterinary medicinal product must be
used and kept out of reach of children. Do not leave unattended filled syringe in the
presence of children. Any uneaten medicated cat food must be disposed of
immediately and the bowl washed thoroughly.
In case of accidental ingestion, particularly by a child, seek medical advice
immediately and show the package leaflet or the label to the physician.
Ciclosporin can trigger hypersensitivity (allergic) reactions.
People with known hypersensitivity to ciclosporin should avoid contact with the
veterinary medicinal product.
Irritation to eyes is unlikely. As precautionary measure avoid contact with eyes. In
case of contact, rinse thoroughly with clean water. Wash hands and any exposed
skin after use.
Special precautions for the protection of the environment:
Not applicable.
Various substances are known to competitively inhibit or induce the enzymes
involved in the metabolism of ciclosporin, in particular cytochrome P450 (CYP 3A 4).
In certain clinically justified cases, an adjustment of the dosage of the veterinary
medicinal product may be required. Ketoconazole is known to increase the blood
concentration of ciclosporin in cats and dogs which is considered to be clinically
relevant. During concomitant use of ketoconazole and ciclosporin the veterinarian
should consider as a practical measure to double the treatment interval if the animal
is on a daily treatment regime.
Macrolides such as erythromycin may increase the plasma levels of ciclosporin up to
twofold.
Certain inducers of cytochrome P450, anticonvulsants and antibiotics (e.g.
trimethoprim/sulfadimidine) may lower the plasma concentration of ciclosporin.
Ciclosporin is a substrate and an inhibitor of the MDR1 P-glycoprotein transporter.
Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as
macrocyclic lactones (e.g. ivermectin and milbemycin) could decrease the efflux of
such drugs from blood-brain barrier cells, potentially resulting in signs of CNS toxicity.
In clinical studies with cats treated with ciclosporin and selamectin or milbemycin,
there did not appear to be an association between these drugs’ concomitant use and
neurotoxicity.
Ciclosporin can increase the nephrotoxicity of aminoglycoside antibiotics and
trimethoprim. The concomitant use of ciclosporin is not recommended with these
active ingredients.
Particular attention must be paid to vaccination (see sections 3.3 “Contraindications”
and 3.5 “Special precautions for use”).
Concomitant use of immunosuppressive agents: see section 3.5 “Special precautions
for use”.
AN: 01235/2024 & 01239/2024
involved in the metabolism of ciclosporin, in particular cytochrome P450 (CYP 3A 4).
In certain clinically justified cases, an adjustment of the dosage of the veterinary
medicinal product may be required. Ketoconazole is known to increase the blood
concentration of ciclosporin in cats and dogs which is considered to be clinically
relevant. During concomitant use of ketoconazole and ciclosporin the veterinarian
should consider as a practical measure to double the treatment interval if the animal
is on a daily treatment regime.
Macrolides such as erythromycin may increase the plasma levels of ciclosporin up to
twofold.
Certain inducers of cytochrome P450, anticonvulsants and antibiotics (e.g.
trimethoprim/sulfadimidine) may lower the plasma concentration of ciclosporin.
Ciclosporin is a substrate and an inhibitor of the MDR1 P-glycoprotein transporter.
Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as
macrocyclic lactones (e.g. ivermectin and milbemycin) could decrease the efflux of
such drugs from blood-brain barrier cells, potentially resulting in signs of CNS toxicity.
In clinical studies with cats treated with ciclosporin and selamectin or milbemycin,
there did not appear to be an association between these drugs’ concomitant use and
neurotoxicity.
Ciclosporin can increase the nephrotoxicity of aminoglycoside antibiotics and
trimethoprim. The concomitant use of ciclosporin is not recommended with these
active ingredients.
Particular attention must be paid to vaccination (see sections 3.3 “Contraindications”
and 3.5 “Special precautions for use”).
Concomitant use of immunosuppressive agents: see section 3.5 “Special precautions
for use”.
AN: 01235/2024 & 01239/2024
Do not refrigerate.
Store in the original container in order to protect from light.
The veterinary medicinal product contains fat components from natural origin which
can become solid at lower temperatures. A turbidity or jelly-like formation may occur
below 15 °C which is however reversible at temperatures up to 25 °C. However, this
does not affect either the dosing or the efficacy and safety of the veterinary medicinal
product.
Store in the original container in order to protect from light.
The veterinary medicinal product contains fat components from natural origin which
can become solid at lower temperatures. A turbidity or jelly-like formation may occur
below 15 °C which is however reversible at temperatures up to 25 °C. However, this
does not affect either the dosing or the efficacy and safety of the veterinary medicinal
product.
Not applicable.
AN: 01235/2024 & 01239/2024
AN: 01235/2024 & 01239/2024
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Ciclosporin A
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Atopica 10 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 10 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 100 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 100 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 100 mg/ml Oral Solution for Cats and Dogs
POM-VElanco GmbH
liquid
Cats
Dogs
Atopica 100 mg/ml Oral Solution for Cats and Dogs
POM-VElanco GmbH
liquid
Cats
Dogs
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in anti-inflammatory
Related Medications
Adequan 100 mg/ml Solution for Injection
POM-VPolysulphated Glycosaminoglycan
injection
Rx
Horses
Alcort 0.584 mg/ml Cutaneous Spray, Solution
POM-VHydrocortisone Aceponate
spray
Rx
Dogs
Allevinix 50 mg/ml Solution for Injection for Cattle, Horses, Pigs
POM-VFlunixin
injection
Rx
Cattle
Horses
Allevinix 50 mg/ml Solution for Injection for Cattle, Horses, Pigs
POM-VFlunixin
injection
Rx
Cattle
Horses
Anarthron 100 mg/mL Solution for Injection for Dogs
POM-VPentosan Polysulphate Sodium
injection
Rx
Dogs
Anarthron 100 mg/mL Solution for Injection for Dogs
POM-VPentosan Polysulphate Sodium
injection
Rx
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.